On the recordJune 19, 2018
Mr. Speaker, I yield myself the balance of my time. Mr. Speaker, I think Ms. Tenney's argument a minute ago is smart, it is good policy, it is thoughtful, it is measured, and it is the direction we should go. In other words, if there are incentives that are misaligned, let's understand those and let's absorb them and let's change them. It should not be that there is a financial incentive to offer an opioid or for an opioid to get into a system as opposed to a nonopioid alternative. So, for sure, we need to study this. We need to have a clear understanding. I would like to thank the Members on both sides of the aisle for the work they did, as well as Chairman Brady for his leadership in moving this through the Ways and Means Committee. It is such an important time. With 115 deaths from opioid overdoses every day, everyone knows that time is not our friend. There is an urgency to this. We have to have a clear understanding of what is going on. It is imperative that we identify current practices that prevent the use of nonopioid treatments for pain management and that we reduce financial incentives that have unintentionally led to overprescriptions. Mr. Speaker, I urge my colleagues to support this bill, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Illinois (Mr. Roskam) that the House suspend the rules and pass the bill, H.R. 5723, as amended.…





